Lorenzo Calvetti

Vicenza, 36100, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 37 publications

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.

Journal: The oncologist

Published: September 19, 2025

Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database.

Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 02, 2025

Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer.

Prognostic and predictive implications of tumor suppressor gene alterations in non-small cell lung cancer.

Journal: Scientific reports

Published: April 08, 2025

Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study.

Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT study.

Journal: Frontiers in oncology

Published: May 22, 2024

Radical resection in a patient with stage IIIA non-small cell lung cancer with the EGFR exon 19 deletion mutation after neoadjuvant targeted therapy with osimertinib: a case report.

Radical resection in a patient with stage IIIA non-small cell lung cancer with the EGFR exon 19 deletion mutation after neoadjuvant targeted therapy with osimertinib: a case report.

Journal: Translational lung cancer research

Published: May 07, 2024

MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.

MET exon 14 skipping mutations in non-small-cell lung cancer: real-world data from the Italian biomarker ATLAS database.

Journal: ESMO open

Published: April 01, 2024

Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports.

Efficacy of osimertinib and the role of sequential liquid biopsy in patients diagnosed with NSCLC harboring EGFR and BRAF mutations at baseline: insights from two case reports.

Journal: Frontiers in oncology

Published: December 29, 2023

Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis.

Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis.

Journal: Frontiers in immunology

Published: December 11, 2023

Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent EGFR exon 19 deletion and TP53 comutation: a case report.

Aumolertinib in NSCLC with leptomeningeal involvement, harbouring concurrent EGFR exon 19 deletion and TP53 comutation: a case report.

Journal: Journal of thoracic disease

Published: May 25, 2023

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study.

Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study.

Journal: EClinicalMedicine

Published: March 07, 2023

SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs.

SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs.

Journal: Frontiers in oncology

Published: December 21, 2021

Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.

Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.

Journal: The oncologist

Published: September 05, 2021

Showing 1-12 of 37

Last Updated: 09/26/2026